 TIME |
FDA weighs fate of Qnexa for weight loss, again
WFMJ An FDA advisory panel will now review two years of data; when advisers last voted on Qnexa, only one year's worth of follow-up data was available. The drug combines the appetite suppressant phentermine and the anti-seizure/migraine drug topiramate. Obesity drugs fight for FDA approval FDA to give controversial diet drug second look FDA Says Weight Loss Drug Needs CV Outcome Trial |
View full post on fda – Google News
